Assessment of prognostic markers in benign and malignant melanocytic tumours.

AKADEMISK AVHANDLING
som för avläggande av medicine doktorsexamen vid Karolinska Institutet offentligen försvaras i den lilla föreläsningsalen 1tr, Astrid Lindgrens Sjukhus, Solna
Fredagen den 9 december 2011, kl. 9:15
av Vitalijs Svjatoja
MD, MSc.

Huvudhandledare:
Docent Edneia Tani
Institutionen för Onkologi och Patologi
Karolinska Institutet

Bihandledare:
Prof. Lamber Skoog
Institutionen för Onkologi och Patologi
Karolinska Institutet

Fakultetsopponent:
Prof. Christian Ingvar
Kliniska vetenskaper
Lunds Universitet

Betygsnämnd:
Prof. Erik Larsson
Institution för Immunologi, Genetik och Patologi
Uppsala Universitetet

Prof. Anders Hjerpe
Institution för Laboratoriemedicin
Karolinska Institutet

Docent Giuseppe Masucci
Institutionen för Onkologi och Patologi
Karolinska Institutet

Stockholm 2011
Abstracts.

Cutaneous melanoma is a malignant tumour that arises from pigmented skin cells – melanocytes, represents the most rapidly increasing cancer worldwide which is causing significant public health problem. During the past decade a significant progress has been made in the understanding of genesis and progression of melanocytic lesions. However treatment of malignant melanomas is in a majority of cases limited to surgical excision of the primary tumours or metastases. In advanced metastatic disease there are few treatment options. The present thesis reviews current knowledge on epidemiology, ethiology, pathology and treatment options of the benign and malignant melanocytic tumours and concentrates on the analysis of several molecules that are thought to play a role in the processes of cell growth, apoptosis, division, motility and adhesion as well as regulation of cytoskeletal components, protein phosphorylation, cell-cycle and cell survival. Archival material from fine needle aspirates as well as formalin-fixed tumour tissue was used in the study. Primary benign and malignant melanocytic tumours as well as metastatic melanomas were included in the study. The expression of the following proteins in malignant and benign melanocytic tumours was analyzed: S100, CD40, CD44, Bcl-2, Ki-67, COX-2 and HSP90. The expression patterns of the proteins were correlated to pathomorphological properties of the tumours as well as clinical parameters. Moreover, a presence of the BRAF gene mutation V600 has been analyzed in metastases from malignant melanomas. We found that melanocytic tumours are heterogeneous in respect to expression of the analyzed proteins as well as mutational status. Analysis of biomarkers and genetic aberrations might therefore be of importance for predicting the biological behaviour of the tumours. The results of the study are discussed in the light of eventual prognostic, diagnostic and therapeutic application of the analyzed proteins and mutational status.